
Sandu Pharmaceuticals Downgraded to Strong Sell Amid Flat Financials and Weak Fundamentals
2026-11-17 08:23:13Sandu Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 16 Nov 2026, reflecting deteriorating fundamentals and subdued financial performance. Despite an attractive valuation, the company’s weak quality metrics, stagnant financial trends, and poor technical indicators have prompted a reassessment of its investment appeal.
Read More
Sandu Pharmaceuticals Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals
2026-10-20 08:24:31Sandu Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 19 Oct 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The micro-cap pharmaceutical company’s stock performance continues to lag behind benchmarks, prompting a reassessment across quality, valuation, financial trend, and technical parameters.
Read More
Sandu Pharmaceuticals Ltd Rating Upgraded to Sell Amid Technical Improvements
2026-10-13 08:31:03Sandu Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The micro-cap pharmaceutical company’s recent flat financial performance and long-term underperformance contrast with modest improvements in technical trends, prompting a nuanced reassessment of its outlook.
Read More
Sandu Pharmaceuticals Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals
2026-10-07 08:18:27Sandu Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 6 October 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. Despite a very attractive valuation, the company’s poor long-term growth, flat recent performance, and bearish technical signals have prompted a reassessment of its investment appeal.
Read More
Sandu Pharmaceuticals Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals
2026-09-28 08:06:55Sandu Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 25 Sep 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. Despite a valuation that appears attractive on paper, the company’s faltering operational performance and bearish market signals have prompted a reassessment of its investment appeal.
Read More
Sandu Pharmaceuticals Ltd is Rated Sell
2026-08-27 10:11:02Sandu Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 11 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 August 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSENewspaper publication in respect of Unaudited Financials for the Q and Half Year ended 30th September 2026
Board Meeting Outcome for Outcome Of The Board Meeting Dated 14Th November 2026
14-Nov-2026 | Source : BSEOutcome of the Board Meeting dated 14th November 2026
Statement Of Deviation And Variation Of Funds For Q Ended 30Th September 2026
14-Nov-2026 | Source : BSEstatement of deviation and variation of funds for q ended 30th sept 2026
Corporate Actions
No Upcoming Board Meetings
Sandu Pharmaceuticals Ltd has declared 10% dividend, ex-date: 04 Sep 26
No Splits history available
No Bonus history available
No Rights history available